Intellia Therapeutics
NTLA
112 hedge funds and large institutions have $467M invested in Intellia Therapeutics in 2017 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 40 increasing their positions, 15 reducing their positions, and 13 closing their positions.
215% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 13
167% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 15
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
76% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $3.08M
32% more funds holding
Funds holding: 85 → 112 (+27)
18.38% more ownership
Funds ownership: 48.95% → 67.33% (+18%)
6% more capital invested
Capital invested by funds: $439M → $467M (+$27.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$26.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.8M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$23.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$22.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTP
Global Thematic Partners
New York
|
-$12.5M |
| 2 |
O
OrbiMed
New York
|
-$7.49M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.59M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.82M |
| 5 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$1.19M |
NTLA Hedge Fund Activity: Q4 2017 in Review
112 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2017, worth a combined $467M — up 6.3% from $439M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new NTLA positions and 13 closed out — a net gain of 28 holders — while 40 added to existing stakes and 15 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $26.3M. The largest seller was Global Thematic Partners, exiting entirely with an estimated $12.5M sold.
- 112 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2017, up from 85 in Q3 2017.
- Funds reported $467M of Intellia Therapeutics stock for Q4 2017, up 6.3% quarter-over-quarter.
- 41 funds opened new Intellia Therapeutics positions in Q4 2017 and 13 closed out, a net change of +28 holders.
- The largest Intellia Therapeutics buyer in Q4 2017 was Farallon Capital Management, an estimated $26.3M added.
- The largest Intellia Therapeutics seller in Q4 2017 was Global Thematic Partners, an estimated $12.5M sold.
Based on aggregated 13F filings for Q4 2017.